Literature DB >> 3020312

Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism.

H Scherf, R Pietsch, G Landsberg, H J Kramer, R Düsing.   

Abstract

The present study was performed to investigate the effect of the angiotensin I-converting enzyme inhibitor ramipril on vascular synthesis of prostacyclin (PGI2). Administration of ramipril (Hoe 498) to rats significantly stimulated prostacyclin (PGI2) synthesis, quantified by radioimmunoassay of its stable hydrolysis product 6-keto-PGF1 alpha, by portions of the animals' isolated aorta. This effect was maximal at a dose range of 10(-7) mol/kg ramipril. The addition of the active ramipril metabolite ramipril diacid directly into the incubation buffer at final concentrations of 10(-9), 10(-6), and 10(-4) M resulted in a dose-dependent stimulation of 6-keto-PGF1 alpha released by isolated aortic tissue. Pretreatment of rats with aprotinin (40,000 U s.c. 60 min before the incubations) attenuated the ramipril-induced effect on aortic 6-keto-PGF1 alpha synthesis. Our results show that the angiotensin I-converting enzyme inhibitor ramipril stimulates PGI2 synthesis in vascular tissue and that this effect may be secondary to changes in the activity of the kinin system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020312     DOI: 10.1007/bf01734341

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  15 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.

Authors:  T Unger; T Fleck; D Ganten; R E Lang; F Rettig
Journal:  Arzneimittelforschung       Date:  1984

3.  Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.

Authors:  K Felder; P U Witte
Journal:  Arzneimittelforschung       Date:  1984

4.  Stimulation of arachidonic acid metabolism in rat kidney mesangial cells by bradykinin, antidiuretic hormone, and their analogues.

Authors:  A Uglesity; J I Kreisberg; L Levine
Journal:  Prostaglandins Leukot Med       Date:  1983-01

5.  Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).

Authors:  B A Schölkens; R H Becker; J Kaiser
Journal:  Arzneimittelforschung       Date:  1984

Review 6.  Chemistry of the inhibitors of the renin-angiotensin system.

Authors:  R Geiger
Journal:  Arzneimittelforschung       Date:  1984

Review 7.  Interactions of prostaglandins with the kallikrein-kinin and renin-angiotensin systems.

Authors:  J C McGiff
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

8.  Dietary linoleic acid deprivation: effects on blood pressure and PGI2 synthesis.

Authors:  R Düsing; R Scherhag; K Glänzer; U Budde; H J Kramer
Journal:  Am J Physiol       Date:  1983-02

9.  The converting enzyme inhibitor captopril stimulates prostacyclin synthesis by isolated rat aorta.

Authors:  R Düsing; R Scherhag; G Landsberg; K Glänzer; H J Kramer
Journal:  Eur J Pharmacol       Date:  1983-08-05       Impact factor: 4.432

10.  Release of prostaglandin I2-like activity from the rat aorta: effect of captopril, furosemide, and sodium.

Authors:  J M Sullivan; D R Patrick
Journal:  Prostaglandins       Date:  1981-10
View more
  6 in total

1.  Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril.

Authors:  W Linz; B A Schölkens; J Kaiser; M Just; B Y Qi; U Albus; P Petry
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

Review 2.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

3.  Tonic stimulation of renin gene expression by nitric oxide is counteracted by tonic inhibition through angiotensin II.

Authors:  K Schricker; I Hegyi; M Hamann; B Kaissling; A Kurtz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

4.  Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells.

Authors:  Denis Feliers; Balakuntalam S Kasinath
Journal:  Mol Cell Endocrinol       Date:  2009-09-16       Impact factor: 4.102

5.  Studies on the effect of two angiotensin-converting enzyme inhibitors, captopril and cilazapril, on platelet and vascular prostaglandin metabolism in vivo.

Authors:  B Wagner; H G Eichler; B Schneider; B Blöchl-Daum; B Brenner; S Gasic; K Lechner; P A Kyrle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

Review 6.  Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.

Authors:  W Linz; G Wiemer; J Schaper; R Zimmermann; K Nagasawa; P Gohlke; T Unger; B A Schölkens
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.